Here is the latest shareholding Pattern of GLENMARK PHARMA. For more details, see the GLENMARK PHARMA financial fact sheet and GLENMARK PHARMA share price. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Jun-22 |
3
Sep-22 |
3
Dec-22 |
3
Mar-23 |
3
Jun-23 |
3
Sep-23 |
3
Dec-23 |
3
Mar-24 |
||
---|---|---|---|---|---|---|---|---|---|---|
Indian Promoters | % | 46.65 | 46.65 | 46.65 | 46.65 | 46.65 | 46.65 | 46.65 | 46.64 | |
Foreign Promoters | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Promoters | % | 46.65 | 46.65 | 46.65 | 46.65 | 46.65 | 46.65 | 46.65 | 46.64 | |
Mutual Funds | % | 5.81 | 6.26 | 5.64 | 5.43 | 5.36 | 7.30 | 8.59 | 10.55 | |
Financial institution/Banks/Insurance | % | 0.20 | 4.38 | 4.68 | 4.61 | 3.38 | 2.64 | 1.88 | 2.39 | |
Government | % | 0.00 | 0.00 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | |
FII | % | 24.23 | 23.14 | 23.19 | 22.47 | 25.52 | 24.79 | 23.71 | 21.38 | |
Other | % | 4.49 | 0.30 | 0.38 | 0.35 | 0.37 | 0.38 | 0.45 | 0.42 | |
Total Institution | % | 34.73 | 34.08 | 33.93 | 32.90 | 34.67 | 35.15 | 34.67 | 34.78 | |
Bodies Corporate | % | 1.18 | 1.28 | 1.26 | 1.94 | 2.15 | 2.09 | 2.64 | 2.46 | |
Individuals | % | 16.32 | 16.47 | 16.72 | 16.90 | 15.20 | 14.84 | 14.78 | 14.83 | |
NRIs/OCBs | % | 1.01 | 1.00 | 0.95 | 1.11 | 0.95 | 0.90 | 0.90 | 0.92 | |
ADR/GDR | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Others | % | 0.12 | 0.52 | 0.49 | 0.50 | 0.39 | 0.38 | 0.37 | 0.37 | |
Total Non-Institution | % | 18.63 | 19.27 | 19.42 | 20.45 | 18.69 | 18.21 | 18.69 | 18.58 | |
Total Public | % | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | |
Grand Total | % | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
Pledged Promoter Holding | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Subscriber Feature |
More Pharmaceuticals Company Shareholding Pattern: ZYDUS LIFESCIENCES CIPLA DIVIS LABORATORIES SUN PHARMA DR. REDDYS LAB
Asian shares rose cautiously on Friday as markets sobered up to the idea that U.S. rate cuts were most likely some time away.